Separately, Stifel Nicolaus lifted their target price on shares of Compugen from $3.00 to $4.00 and gave the stock a buy rating in a report on Tuesday, December 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $5.33.
Compugen Stock Performance
Institutional Trading of Compugen
Several hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG raised its stake in Compugen by 12.7% in the 4th quarter. UBS Group AG now owns 314,697 shares of the biotechnology company’s stock worth $623,000 after purchasing an additional 35,443 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Compugen by 58.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 21,700 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,000 shares in the last quarter. Silverarc Capital Management LLC raised its stake in Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 20,000 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in Compugen in the 3rd quarter worth about $71,000. Finally, Kingsview Wealth Management LLC acquired a new stake in Compugen in the 3rd quarter worth about $78,000. Institutional investors and hedge funds own 13.25% of the company’s stock.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Five stocks we like better than Compugen
- How and Why to Invest in Oil Stocks
- 3 attractive stocks that insiders are buying
- Investing in Construction Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.